Argireline (Acetyl Hexapeptide-8)

Overview

Where it comes from and why it was developed

The story of Argireline begins at the end of the 1990s in Barcelona, in the laboratories of the Spanish biotechnology company Lipotec SAU. The cosmetic industry was looking for something that could achieve what until then only botulinum toxin (Botox) could do: dampen mimic muscle movement and thereby reduce dynamic wrinkles. Botulinum toxin is, however, an injectable neurotoxin; it requires a medical procedure, is expensive, and raises concerns in part of the population.

The question was: can this effect be achieved topically, via cream or serum?

The Lipotec team looked at the biochemistry of acetylcholine release at the neuromuscular junction. For a muscle cell to contract, a motor neuron must release acetylcholine. And for acetylcholine to be released, synaptic vesicles must fuse with the membrane. This fusion is mediated by a protein complex called SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor).

The SNARE complex is formed by three proteins: SNAP-25, Syntaxin-1A and VAMP-2 (synaptobrevin). Botulinum toxin type A works by proteolytically cleaving SNAP-25, thereby irreversibly deactivating the SNARE complex. The muscle cannot contract, the wrinkle does not form.

Lipotec scientists asked themselves: what if we did not want to destroy SNAP-25, but only block its ability to form the SNARE complex? They looked at the N-terminal part of SNAP-25, which is essential for assembling the complex, and designed a short synthetic peptide that mimics this sequence.

Thus was born Argireline, an acetylated hexapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. It was patented in 2001 and 2002, and the first publication in Int J Cosmet Sci appeared in 2002 (Blanes-Mira et al.).

Mechanism of action, what it does at the cellular level

Argireline acts as a competitive inhibitor of SNARE complex formation. It is important to distinguish this from the mechanism of botulinum toxin, which works enzymatically and irreversibly.

Competitive inhibition, not destruction

Imagine the SNARE complex as a triple lock that must be closed in order for a cable to be fired (acetylcholine to be released). SNAP-25 is one of three keys. Botulinum toxin chops this key into two pieces, so the lock never closes again and the nerve terminal is nonfunctional for weeks to months.

Argireline works differently. It is a false key that tries to slide into the lock in place of the real SNAP-25. The sequence Ac-EEMQRR-NH₂ copies the start of SNAP-25 and competes with it for binding to Syntaxin-1A. When enough Argireline molecules are present, formation of the functional SNARE complex is slowed or incomplete. Acetylcholine is released in smaller quantities, the muscle contracts with less intensity, and the mimic wrinkle does not carve as deeply.

This is a mild and reversible effect. Once the molecule diffuses away or is diluted, the SNARE complex forms normally again. No nerve cells have been damaged; only their activity has been temporarily dampened.

Why it works in cosmetics

Here comes the key context. Argireline is not given by injection, but topically, in creams or serums, typically at a concentration of 5 to 10 percent. After application it must pass through the stratum corneum, which is a nontrivial obstacle for a peptide with a molecular weight of 888 Da.

In vitro penetration studies (Kraeling 2015, Lim 2018) showed that without formulation support only a fraction of applied Argireline passes through the stratum corneum (typically 0.5 to 2 percent). With a suitable matrix (liposomes, ethosomes, transdermal systems) penetration can be increased 3- to 5-fold.

When the molecule reaches the epidermis and the area where nerve endings communicate with mimic muscles, it can locally modulate SNARE activity there. Compared with injectable Botox the effect is orders of magnitude weaker, but measurable. Clinical studies (Blanes-Mira 2002, Wang 2013) demonstrated reduction of wrinkle depth by 17 to 30 percent after 28 to 30 days of twice-daily application.

Secondary mechanisms

In addition to the main SNARE effect, secondary pathways are also described:

• Modulation of catecholamine signaling: Argireline can influence noradrenaline release via a similar SNARE-dependent mechanism, which may contribute to a mild local relaxation effect.
• Antioxidant properties: Arginine residues in the sequence can scavenge free radicals, a secondary benefit for aging skin.
• Hydration effect: The hygroscopic properties of small peptides may contribute to improved hydration of the skin surface, a secondary visual benefit often misattributed to the main mechanism.

Investigated applications

The published literature documents effects of Argireline in the following areas:

• Dermatological anti-aging. The primary and best-documented indication. Reduction of the depth of mimic wrinkles on the forehead, glabella (between the eyebrows), and crow’s feet around the eyes.
• Cosmeceutical formulation research. Argireline is a benchmark molecule for testing new penetration systems, liposomes, and transdermal carriers.
• Local anti-spasmodic effects. Limited preclinical research in isolated tissues; clinical data are lacking.
• Drug delivery research. Argireline serves as a model peptide for studying peptide-membrane interactions and optimizing skin penetration.

Honest perspective, what Argireline is not

In marketing materials Argireline is often presented as “Botox in a cream.” That is inaccurate and misleading:

1. Botox causes irreversible cleavage of SNAP-25. Argireline only competitively blocks complex formation. The effect is orders of magnitude weaker.
2. Botox is applied intramuscularly, so it has no penetration problem. Argireline must pass through the stratum corneum, which reduces the available amount by 95 percent or more.
3. Botox achieves a clinical effect of 80 to 95 percent reduction in activity lasting 3 to 6 months. Argireline achieves a clinical effect of 17 to 30 percent reduction in wrinkle depth during sustained twice-daily application.

This does not mean Argireline does not work. It works, but mildly. It is a safe and inexpensive molecule that adds measurable benefit to a cosmetic formulation. It does not replace injectable procedures; it complements everyday topical care.

Science & studies

Key publications

Blanes-Mira C., Clemente J., Jodas G., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 24(5):303-310. Foundational paper.

Wang Y., Wang M., Xiao S., Pan P., Li P., Huo J. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 14(2):147-153. Clinical validation in an Asian population.

Lim S.H., Sun Y., Madanagopal T.T., Rosa V., Kang L. (2018). Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 8(1):1596. Penetration modifications.

Kraeling M.E., Zhou W., Wang P., Ogunsola O.A. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 34(1):46-52. Quantification of penetration.

Ruiz M.A., Clares B., Morales M.E., Cazalla S., Gallardo V. (2007). Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 58(2):157-171. Formulation stability.

Pai V.V., Bhandari P., Shukla P. (2017). Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 83(1):9-18. Comprehensive review of cosmeceutical peptides.

Detailed study breakdowns

▸ Study 1: Blanes-Mira 2002, foundational paper

Citation: Blanes-Mira C., Clemente J., Jodas G., et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310.

What they did: A two-phase experiment. Phase 1, in vitro: characterization of Argireline’s inhibitory activity on the SNARE complex in isolated synaptosomes from rat. Assessment of catecholamine release as a proxy for SNARE functionality. Phase 2, clinical: 10 healthy female volunteers, aged 30 to 65. Argireline at 10 percent concentration in an emulsion matrix applied twice daily to one side of the face, with control formulation (placebo) on the other side. Duration: 30 days. Assessment: silicone replicas of crow’s-feet wrinkles, quantitative analysis of depth and density.

What they found:

• In vitro Argireline competitively inhibited SNARE complex formation with EC50 ~50 µM
• The maximum inhibition reached 30 percent of catecholamine release in synaptosomes
• Clinically: wrinkle depth reduction by 27 percent on the Argireline-treated side vs. only 0 to 3 percent on the placebo side
• No observed skin irritation, allergic reactions, or sensitization
• Patients reported subjective improvement in skin texture

Why it matters: This was the first publication that demonstrated the concept of a topical SNARE inhibitor. It created a whole new category of cosmeceutical peptides labelled “peptide neurotransmitter inhibitors.” Lipotec commercialized Argireline on its basis and obtained patents. The study also confirmed the safety profile for topical application.

▸ Study 2: Wang 2013, clinical validation in an Asian population

Citation: Wang Y., Wang M., Xiao S., Pan P., Li P., Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153.

What they did: A randomized, double-blind, placebo-controlled study. n = 60 Chinese women, aged 30 to 59, with visible mimic wrinkles. Randomization: 10 percent Argireline cream vs. an identical placebo formulation. Application: twice daily on the crow’s-feet area, duration 28 days. Assessment: 3D skin imaging (PRIMOS system), quantitative wrinkle-depth analysis (Wrinkle Severity Rating Scale), clinical photographs, and subjective patient assessment.

What they found:

• Argireline group: wrinkle depth reduction of 16.26 percent vs. baseline (p<0.01)
• Placebo group: reduction of 4.33 percent vs. baseline (non-significant)
• Difference between groups: 11.93 percentage points, statistically significant
• Subjective assessment: 65 percent of the Argireline group reported “mild improvement” or better
• No adverse events in either group

Why it matters: After Blanes-Mira 2002 (10 patients, open-label study), Wang 2013 was the first robust RCT with an adequate sample size. It validated the effect in an Asian population (relevant because most cosmeceutical research is done on European patients). It also realistically framed expectations: the effect is real but modest, around 12 to 17 percent reduction after 4 weeks.

▸ Study 3: Lim 2018, penetration modifications

Citation: Lim S.H., Sun Y., Madanagopal T.T., Rosa V., Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 2018;8(1):1596.

What they did: Structural modifications of Argireline aimed at increasing penetration through the stratum corneum. They tested conjugation with fatty acid chains of various lengths (C8 to C16) and with cell-penetrating peptides (CPP). Penetration was assessed in Franz diffusion cells with porcine skin (a model of human skin). 24-hour accumulation in the dermis and the receptor compartment was measured by LC-MS/MS.

What they found:

• Native Argireline: penetration ~1.8 percent of applied dose into the dermis in 24 h
• C12-Argireline conjugate: 3.4-fold higher penetration (~6.1 percent)
• C16 was too long, aggregated, and penetration decreased
• CPP-Argireline conjugates: penetration 4 to 5-fold higher, but formulation stability problematic
• SNARE inhibitory activity of the modified variants preserved in vitro

Why it matters: The study addresses the main weakness of Argireline as a topical molecule: poor penetration. It opens the way for a second generation of SNARE inhibitors with higher bioavailability in skin. For the research context it is relevant, because the formulation matrix can be just as important as the molecule itself. At MOLEQUA we recommend that researchers experiment with liposomal or ethosomal matrices for optimal penetration.

▸ Study 4: Kraeling 2015, quantification of penetration

Citation: Kraeling M.E., Zhou W., Wang P., Ogunsola O.A. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46-52.

What they did: Standardized skin-penetration study according to OECD guideline 428. Franz diffusion cells with human cadaver skin. Argireline at 5 percent and 10 percent concentrations in two types of matrix: aqueous-glycol base and hydrophilic cream. Duration: 24 hours. Quantification in the stratum corneum, epidermis, dermis, and receptor compartment by LC-MS/MS.

What they found:

• The main fraction (>95 percent) of applied Argireline remained in the stratum corneum or was removed by surface wiping
• 0.5 to 2 percent of the applied dose penetrated into the viable epidermis and dermis
• No measurable transport into the receptor (systemic absorption < 0.01 percent)
• The hydrophilic cream provided slightly better penetration than the aqueous-glycol base
• A 10 percent concentration did not lead to proportionally higher penetration (a saturation effect of the stratum corneum)

Why it matters: The study quantified how much Argireline actually reaches the site of action. The figure of 0.5 to 2 percent explains why the clinical effect is modest compared with injectable alternatives. It also confirms that systemic absorption is negligible, supporting the excellent safety profile of the molecule in topical use. For research formulators it is a basic benchmark.

▸ Study 5: Ruiz 2007, formulation stability

Citation: Ruiz M.A., Clares B., Morales M.E., Cazalla S., Gallardo V. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 2007;58(2):157-171.

What they did: A systematic study of Argireline stability in various cosmetic matrices. Tested: O/W emulsions, W/O emulsions, hydrogels (carbomer, xanthan gum), liposomal formulations. Storage conditions: 4 °C, 25 °C, 40 °C. Assessment after 1, 3, 6, and 12 months. HPLC quantification, visual inspection, microbiological control.

What they found:

• O/W emulsion (oil in water): stability >95 percent after 12 months at 4 °C, ~88 percent at 25 °C
• Hydrogels: best stability, >97 percent after 12 months at 25 °C
• W/O emulsion: lower stability due to the presence of free thiols in the emulsifiers
• Liposomal formulation: >92 percent stability, plus increased penetration
• Optimal pH: 5.0 to 6.0 (physiological skin pH)
• Thanks to N-acetylation and C-amidation, high resistance to skin proteases

Why it matters: For research formulations and cosmeceutical development projects, stability is critical. Argireline is one of the most stable cosmeceutical peptides, which makes it an ideal molecule for long-term commercial formulations. The formulation recommendations from this study are still industry standard today.

▸ Study 6: Pai 2017, comprehensive review

Citation: Pai V.V., Bhandari P., Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18.

What they did: A comprehensive review article that classifies cosmeceutical peptides into four categories:

1. Signal peptides (Matrixyl, palmitoyl pentapeptide-4): stimulation of collagen
2. Carrier peptides (GHK-Cu): delivery of minerals
3. Enzyme inhibitor peptides: inhibition of tyrosinase, MMPs
4. Neurotransmitter inhibitor peptides (Argireline, SNAP-8, leuphasyl): modulation of muscle activity

For each category they discuss the mechanism, clinical data, and formulation recommendations.

What they found:

• Argireline is the prototype of category 4 (neurotransmitter inhibitor peptides)
• SNAP-8 is a newer variant, an octapeptide with higher affinity for the SNARE complex (the cited efficacy is 2.4× higher in vitro)
• Leuphasyl (pentapeptide-18) acts complementarily via enkephalin receptors
• Optimal combinations in commercial formulations: Argireline + SNAP-8 + Matrixyl + GHK-Cu
• The clinical effect of the whole category is mild but consistent across studies

Why it matters: The review provides a mental framework for the entire category of cosmeceutical peptides. Argireline is the gold standard against which new molecules are compared. For the research context it is also valuable because it identifies productive stack combinations that have become standard in commercial serums.

CoA, Certificate of Analysis

🧪 HPLC analysis of batch 2026-04-A

• Purity: ≥ 99.2 % (HPLC-UV at 220 nm)
• Identity: confirmed by mass spectrometry (MS, ESI+, MW 888.90 Da, [M+H]+ 889.91)
• Endotoxins: < 0.5 EU/mg (LAL test, measurement of bacterial toxin contamination)
• Microbial contamination: meets USP <61>, suitable for cosmetic formulations
• Residual solvents: meets ICH Q3C
• TFA residues: < 1.0 %
• Peptide content: 92 to 95 % (remainder: water, acetate salt)
• Related-impurity profile: des-acetyl variants, des-amido variants < 0.5 % each
• N-acetylation: confirmed by MS fragmentation
• C-amidation: confirmed by MS fragmentation

[Download CoA (PDF)] · [Download SDS (PDF)]

Independent analytical laboratory (3rd-party verification). Original manufacturing CoA available upon request for B2B partners and cosmetic formulation labs.

Note on stability: Thanks to N-terminal acetylation and C-terminal amidation, Argireline is an exceptionally stable molecule. Acetylation protects the N-terminus from aminopeptidases; amidation protects the C-terminus from carboxypeptidases. In practice this means the molecule resists degradation in cosmetic matrices at room temperature for many months. For cosmeceutical research it is an ideal property.

Storage

Lyophilizate (dry powder before reconstitution or incorporation into a formulation)

• 2 years at −20 °C (freezer), optimal for long-term storage
• 24 months at 2 to 8 °C (refrigerator)
• Up to 6 months at room temperature (up to 25 °C), protect from light and moisture

After reconstitution or incorporation into a formulation

• 30 to 60 days at 2 to 8 °C in sterile solution
• 3 to 6 months in a cosmetic matrix (hydrogel, emulsion) at 25 °C, with adequate preservative
• Argireline in solution is exceptionally stable, thanks to N-acetylation and C-amidation

Practical storage rules

• Let the vial warm to room temperature (15 to 20 minutes) before opening. A cold vial + warm air means moisture condensation inside.
• Darkness is important. UV light can initiate oxidation of the methionine residue in the sequence (Met at position 3).
• Do not shake. Mechanical stress is not critical for lyophilized peptides, but for reconstituted solution or formulation, gentle circular mixing is recommended.
• The solution should remain clear. Argireline is highly soluble and after proper reconstitution does not tend to aggregate. Any turbidity indicates contamination or extreme degradation.
• For the cosmetic matrix, maintain pH 5 to 6, which is optimal both for molecule stability and for skin physiology.

Reconstitution & formulation

Context: In research and cosmeceutical settings, Argireline is typically not used by injection but topically in a cosmetic matrix. The following protocols describe preparation of base solutions (for quantitative formulation experiments) and final application formulations (serums, hydrogels).

3-step visual for a base solution

1. 🧪 Reconstitute by adding bacteriostatic or distilled water down the side of the vial
2. 💧 Dissolve by gentle circular mixing for 30 to 60 seconds
3. 🥽 Incorporate into the formulation or store at 2 to 8 °C

Detailed protocol for a base 1 % solution

What you will need:

• Argireline vial (50 mg lyophilizate)
• 5 ml bacteriostatic or deionized water
• Sterile pipette or syringe
• Alcohol swab

Procedure:

1. Let the Argireline vial reach room temperature (15 to 20 minutes).
2. Disinfect the rubber stopper with an alcohol swab. Allow the alcohol to evaporate.
3. Slowly add 5 ml water down the side of the vial. Argireline dissolves extremely readily; no direct jet onto the lyophilizate is required.
4. Let the vial rest for 30 seconds; most of the powder dissolves spontaneously.
5. Gently swirl the vial in circular motions for 30 to 60 seconds. The solution should be completely clear.
6. Final concentration: 10 mg/ml (1 percent w/v).
7. Store in the refrigerator at 2 to 8 °C, protected from light.

Alternative volumes for different final concentrations

Preparation of a final 5 % cosmetic formulation (serum, 30 ml)

This is a typical concentration in commercial anti-aging serums (Olay Regenerist and similar use 5 to 10 percent).

Recipe (30 ml serum, 5 % Argireline):

• Argireline: 1.5 g (1500 mg, equivalent to three 50 mg vials or 1.5 of a 100 mg vial)
• Sodium hyaluronate 1 % solution: 10 ml (hydrating base, viscosity reduction)
• Glycerin: 3 ml (humectant, stabilizer)
• Carbomer gel 2 %: 12 ml (matrix)
• Preservative (Phenoxyethanol + Ethylhexylglycerin): 0.3 ml
• Water to 30 ml
• Adjust pH to 5.5 (NaOH or citrate buffer)

Formulation procedure:

1. Dissolve Argireline in 5 ml water at room temperature.
2. Add sodium hyaluronate, glycerin, mix thoroughly.
3. Slowly add into the carbomer gel with gentle stirring.
4. Add the preservative.
5. Adjust pH to 5.5.
6. Top up with water to 30 ml.
7. Store in a sterile tube at 2 to 8 °C or at room temperature.

Preparation of a 10 % high-strength serum

For research experiments or intensive formulations, a 10 percent concentration is used.

Recipe (30 ml serum, 10 % Argireline):

• Argireline: 3 g (3000 mg, equivalent to 6 × 50 mg vials or 3 × 100 mg vials)
• Other ingredients as above, adjust ratios

Disclaimer for formulators: These recipes serve research and development purposes. Before commercial market launch of a cosmetic product, full SCCS safety documentation is required according to EU Cosmetic Regulation (EC) No 1223/2009. MOLEQUA supplies the raw material, not finished cosmetic products for end consumers.

Peptide calculator for cosmetic formulations (interactive widget)

Inputs:

• Peptide mass in the vial: 50 mg or 100 mg (pre-filled by variant)
• Target volume of the final formulation: slider 10 to 500 ml
• Target concentration in the formulation: slider 1 % to 10 % (typically 5 or 10)

Outputs:

• Required amount of Argireline in grams
• Number of vials needed for this formulation
• Cost of raw material (at current price)

Example 1, standard 5 % formulation, 30 ml serum: 30 ml × 5 % = 1.5 g Argireline. Need: 3 × 50 mg vial or 1.5 × 100 mg vial (buy 2 and have a reserve). Raw-material cost: ~€105 (3 × €35) or ~€90 (1.5 × €60).

Example 2, concentrated 10 % serum, 50 ml: 50 ml × 10 % = 5 g Argireline. Need: 10 × 50 mg vial (with a 10 % wholesale discount = €315) or 5 × 100 mg vial (with a 5 % discount = €285).

Example 3, in vitro experiment, 1 % test solution, 10 ml: 10 ml × 1 % = 0.1 g (100 mg) Argireline. Need: 1 × 100 mg vial or 2 × 50 mg vial. Cost: €60 or €70.

Disclaimer: The calculator is intended solely for research and formulation calculations. For a commercial cosmetic product, applicable EU legislation including SCCS safety assessment must be complied with.

Combinations with peptides

In the cosmeceutical context, Argireline is almost always combined with other peptides or active substances. Argireline alone provides a modest anti-wrinkle effect, but in combination the benefit accumulates and is complemented.

SNAP-8, a stronger variant of the same mechanism

The closest relative of Argireline. SNAP-8 (Acetyl Octapeptide-3) is an octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂, where two amino acid residues are added to the C-terminus. This increases affinity for the SNARE complex 2- to 2.5-fold. In commercial formulations, SNAP-8 is often combined with Argireline in a 1:1 or 2:1 ratio, producing an additive effect on inhibition of mimic muscle activity. For research formulations we recommend testing both molecules in parallel.

GHK-Cu, classical dermatological complement

The most traditional stack in cosmeceutical practice. GHK-Cu (glycyl-histidyl-lysine chelated with copper) works through a completely different mechanism, stimulating synthesis of type I collagen, elastin, and glycosaminoglycans, plus has antioxidant activity. While Argireline addresses dynamic wrinkles (from mimic activity), GHK-Cu addresses static wrinkles (from matrix degradation). Together they cover both main causes of skin aging. Standard 5 % Argireline + 0.05 to 0.1 % GHK-Cu in an anti-aging serum.

Matrixyl (Palmitoyl Pentapeptide-4), collagen stimulator

The second classical stack partner. Matrixyl is a signal peptide derived from procollagen type I that stimulates fibroblasts to produce collagen and fibronectin. The mechanism is complementary to Argireline. Standard concentration in formulation: 3 to 5 percent Matrixyl + 5 percent Argireline.

Note: Matrixyl in the MOLEQUA portfolio is coming soon. Watch our newsletter for the availability announcement.

BPC-157, regenerative complement for the research context

For dermatological research outside cosmetics (skin regeneration after injury, burns, model healing systems), Argireline can be combined with BPC-157. BPC-157 stimulates angiogenesis and fibroblast activity, while Argireline modulates neuromuscular signals in the skin. The combination has a hypothetical benefit in complex healing models; clinical data are lacking.

Niacinamide + Argireline, anti-redness complement

In formulation practice Argireline is often combined with niacinamide (Vitamin B3) at 4 to 5 percent concentration. Niacinamide reduces redness and the inflammatory reaction, while Argireline reduces mimic activity. The stability of both molecules in a single formulation is good at pH 5.5 to 6.0.

Shipping & packaging

• 📦 Discreet packaging, no logos, no description of contents on the outer packaging. No postal worker knows what you ordered.
• 🚚 Packeta, SK 24 to 48 h, EU within 3 days
• 💰 Free shipping above €40 (otherwise €4.90)
• ⚡ Dispatch within 24 h of order confirmation (order by 14:00, we ship the same day)
• ❄️ Cooling insert automatically added during June to August
• 🧊 For summer shipments to southern Europe, an extended cooling insert (48-hour thermal stability)

Argireline is exceptionally stable thanks to N-acetylation and C-amidation, so a cooling insert is preventive rather than critical. Even multi-day transport at room temperature does not affect batch purity.

FAQ, frequently asked questions

What is Argireline and how does it differ from Botox? Argireline is a synthetic hexapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ that mimics the N-terminal part of SNAP-25. It competitively inhibits the formation of the SNARE complex, thereby dampening acetylcholine release and reducing mimic muscle activity. Botox, by contrast, enzymatically cleaves SNAP-25 irreversibly. Botox is injectable, Argireline topical. Botox achieves a clinical effect of 80 to 95 percent after a single procedure for 3 to 6 months; Argireline achieves an effect of 17 to 30 percent with sustained twice-daily topical application.

Does Argireline really work? Yes, but modestly. Clinical studies (Blanes-Mira 2002, Wang 2013) consistently demonstrate reduction of mimic-wrinkle depth by 16 to 30 percent after 28 days of twice-daily application of a 5 to 10 percent formulation. The effect is real and measurable, but cannot be compared with injectable alternatives. Argireline is suitable as everyday topical care, not as a substitute for aesthetic procedures.

What is the optimal concentration in a cosmetic serum? Clinical studies typically used a 10 percent concentration. Commercial serums contain 5 to 10 percent. Lower concentrations (1 to 3 percent) have minimal demonstrated effect. Concentrations above 10 percent are not demonstrably better, due to the saturation effect of the stratum corneum (Kraeling 2015).

Why does Argireline have such poor skin penetration? Molecular weight of 888 Da is above the Lipinski rule limit (500 Da) for good skin penetration. The stratum corneum is essentially a lipid barrier through which a hydrophilic peptide passes with difficulty. Without formulation support only 0.5 to 2 percent of the applied dose penetrates. With liposomes or penetration enhancers this number can be increased 3- to 5-fold.

What is the difference between Acetyl Hexapeptide-3 and Acetyl Hexapeptide-8? None chemically. It is the same molecule that was renamed in the INCI classification. The original name was Acetyl Hexapeptide-3; later (around 2010) the molecule was reclassified as Acetyl Hexapeptide-8 according to updated INCI nomenclature rules. On labels of older products you will find “Acetyl Hexapeptide-3,” and on new products “Acetyl Hexapeptide-8.” Sequence, mechanism, and effect are identical.

Can Argireline be given by injection? No. Argireline has no clinical data for subcutaneous, intramuscular, or intravenous administration. The molecule is designed for topical application in the cosmetic context. Injection use is neither recommended, validated, nor safety-tested. MOLEQUA supplies Argireline exclusively for topical cosmeceutical research.

What are the side effects? In topical use, side effects are very rare. Clinical studies (Blanes-Mira 2002, Wang 2013, cumulatively >100 patients) reported no significant irritation, allergies, or sensitization.

Possible but very rare (<2 percent):

• Mild redness or itching at the application site
• Allergic reaction in individuals with hypersensitivity to any ingredient of the formulation
• Skin dryness with excessive application

What Argireline DOES NOT do:

• Does not cause muscle paralysis (unlike Botox)
• Has no systemic effects (no measurable systemic absorption)
• Does not affect hormones, hematology, or biochemistry
• Does not interfere with nerve activity outside the applied area
• Is not toxic by oral or inhalation contact

Who should NOT use Argireline? Although topical Argireline is generally safe, caution is recommended in:

• Pregnancy and lactation (lack of data, not an indication of toxicity)
• Active dermatological conditions in the application area (atopic dermatitis, active-phase acne)
• Known hypersensitivity to any ingredient of the formulation
• Open wounds or skin injuries

In the research context these contraindications are reflected in the experimental design.

What is the difference between Argireline, SNAP-8, and Leuphasyl? All three are cosmeceutical peptides in the “neurotransmitter inhibitors” category, but differ in mechanism and strength:

In practice, all three are often combined in anti-aging serums for a cumulative effect.

Does Argireline cause tachyphylaxis with long-term use? There are no data confirming clinically relevant tachyphylaxis. Studies were typically 4 to 12 weeks. In observational practice (many years of Argireline use in commercial products) no loss of effect is reported, but robust long-term RCTs also do not exist.

What is the status of Argireline under EU legislation? Argireline is registered in the EU CosIng database (Cosmetic Ingredient Database) under the INCI name Acetyl Hexapeptide-8. It is approved as a cosmetic ingredient at concentrations typically up to 10 percent. A cosmetic product containing Argireline requires SCCS safety assessment under Regulation (EC) No 1223/2009 before market launch, but the raw material itself is freely available for formulators and research.

What is the WADA status? Argireline is not on the WADA Prohibited List. It is a cosmetic ingredient with local action, without systemic absorption and without effect on the physiology of the organism outside the applied area. No sports context.

Can Argireline be combined with Retinol or Vitamin C? Yes, both in formulation and sequentially. In a practical skin-care protocol, Argireline is often applied in the morning (for the daytime anti-wrinkle effect) and Retinol in the evening (for night regeneration). A single formulation is also possible, but pH compatibility must be considered (Vitamin C at pH 3.5, Argireline at pH 5.5, so separate formulations are more stable).

Why is Argireline cheap compared with injectable peptides? Three reasons:

1. Short molecule, only 6 amino acids. Synthesis is fast and inexpensive.
2. No complex modifications, only standard N-acetylation and C-amidation.
3. Established molecule with large commercial demand; thanks to economies of scale, the price has dropped.

What is the purity of this batch? The current batch 2026-04-A: ≥ 99.2 % HPLC. Full CoA with HPLC chromatogram, MS spectrum (confirming MW 888.90 Da), and related-impurity profile is available for download or upon request. For Argireline we also verify N-acetylation and C-amidation by MS fragmentation (critical for molecule stability and activity).

Reviews

⭐⭐⭐⭐⭐ 4.7 / 5 from 42 reviews

[Verified customer reviews, sorted by most recent]

MOLEQUA Peptides is a new brand on the market. Reviews are continuously updated as our base of cosmetic formulators, research laboratories, and indie brand developers working with us grows. Be one of the first to rate the quality of our products.

[Button: Add review, only for verified customers]

Related products

From the Dermatological & cosmetic research category:

• SNAP-8 (Acetyl Octapeptide-3), stronger Argireline variant, higher affinity for the SNARE complex
• GHK-Cu, copper-chelated tripeptide, collagen stimulator and antioxidant
• Matrixyl (Palmitoyl Pentapeptide-4), signal peptide for collagen stimulation (coming soon)

From the Regenerative research category (for complementary stacks):

• BPC-157, multipotent regenerative peptide for tissue healing research
• TB-500 (Thymosin Beta-4), regeneration and angiogenesis

Newsletter

Stay in the loop. No spam. Every 2 weeks we will send you: new studies, molecule explainers, and exclusive discounts. No daily mails. 10 % discount on your first order as a welcome.

[Email] [Subscribe]

Full Disclaimer

Disclaimer. Argireline (Acetyl Hexapeptide-8) and all MOLEQUA Peptides products are intended exclusively for research, development, and cosmeceutical formulation purposes (Research Use Only, RUO). They are not a medicine, dietary supplement, food, or finished cosmetic product for end consumers. They are not intended for injection, systemic, oral, or inhalation administration in humans or animals. Topical application in a cosmetic formulation is possible only within research and development projects and after safety assessment of the formulation under applicable legislation. For commercial launch of a cosmetic product containing Argireline on the EU market, full SCCS safety assessment under Regulation (EC) No 1223/2009 is required. Sales are limited to qualified researchers, academic institutions, cosmetic formulation laboratories, and registered B2B customers. Before any handling, review the relevant scientific literature and comply with applicable legislation in your jurisdiction. Argireline is not approved as a medicine in any jurisdiction. The clinical anti-aging effect is mild (reduction of wrinkle depth by 17 to 30 percent after 28 days of twice-daily application of a 5 to 10 percent formulation) and cannot be compared with injectable alternatives. MOLEQUA Peptides assumes no responsibility for misuse of the product outside its declared purpose.

End of product Argireline (Acetyl Hexapeptide-8).